• Title/Summary/Keyword: Cancer radiotherapy

Search Result 1,775, Processing Time 0.031 seconds

A Case of Tumor Recurrence at the Tracheotomy Site in Tonsil Cancer Patient (편도암 치료 후 기관절개 부위에서 재발한 1예)

  • Baek, Seung Jae;Park, Yoon Ah;Lee, Jae Woo;Lee, Young Sub;Bong, Jeong Pyo
    • Korean Journal of Head & Neck Oncology
    • /
    • v.32 no.1
    • /
    • pp.21-23
    • /
    • 2016
  • The aim of this report was to present a rare case of a tracheotomy site recurrence after operation and post-operative radiotherapy in head and neck squamous cell carcinoma patient. Tracheotomy site recurrence other than subglottic cancer is very rare in head and neck cancer patient. The granulation tissue around tracheotomy was a fertile "soil" for tumor cell implantation. Midline mucosal sparing block which was used to decreased acute toxicity during post-operative radiotherapy could be facilitating the tumor cell implantation. The head and neck surgeon should try every effort to reduce contamination of cancer cells during operation and consider the entire operative field should be included in post-operative radiation portals.

The emerging role of myeloid-derived suppressor cells in radiotherapy

  • Kang, Changhee;Jeong, Seong-Yun;Song, Si Yeol;Choi, Eun Kyung
    • Radiation Oncology Journal
    • /
    • v.38 no.1
    • /
    • pp.1-10
    • /
    • 2020
  • Radiotherapy (RT) has been used for decades as one of the main treatment modalities for cancer patients. The therapeutic effect of RT has been primarily ascribed to DNA damage leading to tumor cell death. Besides direct tumoricidal effect, RT affects antitumor responses through immune-mediated mechanism, which provides a rationale for combining RT and immunotherapy for cancer treatment. Thus far, for the combined treatment with RT, numerous studies have focused on the immune checkpoint inhibitors and have shown promising results. However, treatment resistance is still common, and one of the main resistance mechanisms is thought to be due to the immunosuppressive tumor microenvironment where myeloid-derived suppressor cells (MDSCs) play a crucial role. MDSCs are immature myeloid cells with a strong immunosuppressive activity. MDSC frequency is correlated with tumor progression, recurrence, negative clinical outcome, and reduced efficacy of immunotherapy. Therefore, increasing efforts to target MDSCs have been made to overcome the resistance in cancer treatments. In this review, we focus on the role of MDSCs in RT and highlight growing evidence for targeting MDSCs in combination with RT to improve cancer treatment.

The Role of Modern Radiotherapy Technology in the Treatment of Esophageal Cancer

  • Moon, Sung Ho;Suh, Yang-Gun
    • Journal of Chest Surgery
    • /
    • v.53 no.4
    • /
    • pp.184-190
    • /
    • 2020
  • Radiation therapy (RT) has improved patient outcomes, but treatment-related complication rates remain high. In the conventional 2-dimensional and 3-dimensional conformal RT (3D-CRT) era, there was little room for toxicity reduction because of the need to balance the estimated toxicity to organs at risk (OARs), derived from dose-volume histogram data for organs including the lung, heart, spinal cord, and liver, with the planning target volume (PTV) dose. Intensity-modulated RT (IMRT) is an advanced form of conformal RT that utilizes computer-controlled linear accelerators to deliver precise radiation doses to the PTV. The dosimetric advantages of IMRT enable better sparing of normal tissues and OARs than is possible with 3D-CRT. A major breakthrough in the treatment of esophageal cancer (EC), whether early or locally advanced, is the use of proton beam therapy (PBT). Protons deposit their highest dose of radiation at the tumor, while leaving none behind; the resulting effective dose reduction to healthy tissues and OARs considerably reduces acute and delayed RT-related toxicity. In recent studies, PBT has been found to alleviate severe lymphopenia resulting from combined chemo-radiation, opening up the possibility of reducing immune suppression, which might be associated with a poor prognosis in cases of locally advanced EC.

Running of high patient volume radiation oncology department during COVID-19 crisis in India: our institutional strategy

  • Gupta, Manoj;Ahuja, Rachit;Gupta, Sweety;Joseph, Deepa;Pasricha, Rajesh;Verma, Swati;Pandey, Laxman
    • Radiation Oncology Journal
    • /
    • v.38 no.2
    • /
    • pp.93-98
    • /
    • 2020
  • Purpose: Due to COVID 19 pandemic, the treatment of cancer patients has become a dilemma for every oncologist. Cancer patients are at an increased risk of immunosuppression and have a higher risk to acquire any infection. There are individual experiences from some centers regarding the management of cancer patients during such a crisis. So we have developed our institutional strategy to balance between COVID and cancer management. Materials and Methods: Radiation Oncology departmental meeting was held to prepare a consensus document on Radiotherapy schedules and department functioning during this pandemic. Results: Strategies were taken in form of following areas were steps need to be taken to decrease risk of infection, categorise treatment on the basis of priority, radiotherapy schedules modification, academic meetings and management of COVID positive patient/personnel in Radiation Oncology department. Conclusion: We hope to strike the balance in overcoming both the battles and emerge as winners. Stringent long term follow up will be done for assessing the response or any unforeseen treatment related sequelae.

Hypothyroidism after Treatment for Head and Neck Cancer (두경부암 치료후 발생하는 갑상선기능저하증)

  • 조재식;이상철;임상철;김종식;박종부;심우진
    • Korean Journal of Bronchoesophagology
    • /
    • v.3 no.1
    • /
    • pp.101-108
    • /
    • 1997
  • Hypothyroidism is not uncommon complication of therapy for head and neck cancer. A series of 52 patients treated with either radiotherapy alone or combined with surgery was retrospectively studied. Diagnostic procedure included total T3, T4 and TSH measured by radioimmunoassay. The rate of hypothyroidism was 25% (subclinical 15.4%, clinical 9.6%). The incidence of hypothyroidism increased to 40% when radiotherapy was combined with surgery. Risk factors influenced a high incidence of hypothyroidism were : tumor stage, primary tumor site, combination of radiotherapy and surgery (especially combined with laryngectomy). We advocate routine monitoring of head md neck cancer patients for hypothyroidism after treatment and recommend levothyroxine replacement therapy for subclinical hypothyroidism.

  • PDF

Comparison of Dose Statistics of Intensity-Modulated Radiation Therapy Plan from Varian Eclipse Treatment Planning System with Novel Python-Based Indigenously Developed Software

  • Sougoumarane Dashnamoorthy;Karthick Rajamanickam;Ebenezar Jeyasingh;Vindhyavasini Prasad Pandey;Kathiresan Nachimuthu;Imtiaz Ahmed;Pitchaikannu Venkatraman
    • Progress in Medical Physics
    • /
    • v.33 no.3
    • /
    • pp.25-35
    • /
    • 2022
  • Purpose: Planning for radiotherapy relies on implicit estimation of the probability of tumor control and the probability of complications in adjacent normal tissues for a given dose distribution. Methods: The aim of this pilot study was to reconstruct dose-volume histograms (DVHs) from text files generated by the Eclipse treatment planning system developed by Varian Medical Systems and to verify the integrity and accuracy of the dose statistics. Results: We further compared dose statistics for intensity-modulated radiotherapy of the head and neck between the Eclipse software and software developed in-house. The dose statistics data obtained from the Python software were consistent, with deviations from the Eclipse treatment planning system found to be within acceptable limits. Conclusions: The in-house software was able to provide indices of hotness and coldness for treatment planning and store statistical data generated by the software in Oracle databases. We believe the findings of this pilot study may lead to more accurate evaluations in planning for radiotherapy.

Recent Status of Cancer Treatment Using High Energy Radiotherapy Machine (가속기(加速器)를 이용(利用)한 암치료기술(癌治療技術) 현황(現況))

  • Yoo, Seong-Yul
    • Journal of Radiation Protection and Research
    • /
    • v.11 no.1
    • /
    • pp.83-89
    • /
    • 1986
  • High energy radiation therapy using accelerator or radioioisotope teletherapy unit is now one of the most important modality in the field dealing with human malignant tumor. It's successful technology overcomes incurable disease to change into curable disease not only by the improvement of clinical technique but also by the development of radiation physics and biology. The author presented the principles of radiation therapy by means of basic knowledge of medicine. physics and biology, described the various ways to improve the result of radiation therapy, and reviewed recent status of radiotherapy field in Korea.

  • PDF

Protective Effect of Melatonine Against Radiation Induced Nephrotoxicity in Rats

  • Kucuktulu, Eda;Yavuz, Aydin Ali;Cobanoglu, Umit;Yenilmez, Engin;Eminagaoglu, Selcuk;Karahan, Caner;Topbas, Murat;Kucuktulu, Uzer
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.13 no.8
    • /
    • pp.4101-4105
    • /
    • 2012
  • Purpose: The degree of radiation injury to kidneys which are located within the limits of radiotherapy area is determined by the volume and the dose of radiation to which the organ is exposed. When the tolerance dose of the kidney is exceeded after a latent period of 6 months acute nephritis develops and after 18 months chronic nephritis ensues. Melatonin is known to prevent the oxidative injury of toxins and radiotherapy with its free radical scavenging capacity. Methods and Materials: In this study 8 weeks old 24 Sprague -Dawley rats were allocated into 4 groups: Control group; Radiotherapy group (20 Gy bilaterally in 5 fractions); Melatonin group (10 mg/kg intraperitoneally), and Melatonin+radiotherapy group (20 Gy Radiotherapy in 5 fractions+ melatonin 10 mg/kg intraperitoneally). After a follow-up period of 6 months BUN was determined in all groups. After rats were euthanized the kidneys were removed for histopathological examination under both light and electron microscopes. Results: After 6 months follow-up, both at light and electron microscopy levels, the rats in radiotherapy+melatonin group were significantly protected against the radiation injury comparing to radiotherapy group (p<0.05). Conclusion: It was shown in this experimental model that melatonin has protective effects against radiation injury to kidneys.

Radiation-induced brain injury: retrospective analysis of twelve pathologically proven cases

  • Lee, Dong-Soo;Yu, Mi-Na;Jang, Hong-Seok;Kim, Yeon-Sil;Choi, Byung-Ock;Kang, Young-Nam;Lee, Youn-Soo;Kim, Dong-Chul;Hong, Yong-Kil;Jeun, Sin-Soo;Yoon, Sei-Chul
    • Radiation Oncology Journal
    • /
    • v.29 no.3
    • /
    • pp.147-155
    • /
    • 2011
  • Purpose: This study was designed to determine the influencing factors and clinical course of pathologically proven cases of radiation-induced brain injury (RIBI). Materials and Methods: The pathologic records of twelve patients were reviewed; these patients underwent surgery following radiotherapy due to disease progression found by follow-up imaging. However, they were finally diagnosed with RIBI. All patients had been treated with 3-dimensional conventional fractionated radiotherapy and/or radiosurgery for primary or metastatic brain tumors with or without chemotherapy. The histological distribution was as follows: two falx meningioma, six glioblastoma multiform (GBM), two anaplastic oligodendroglioma, one low grade oligodendroglioma, and one small cell lung cancer with brain metastasis. Results: Radiation necrosis was noted in eight patients and the remaining four were diagnosed with radiation change. Gender (p = 0.061) and biologically equivalent dose $(BED)_3$ (p = 0.084) were the only marginally influencing factors of radiation necrosis. Median time to RIBI was 7.3 months (range, 0.5 to 61 months). Three prolonged survivors with GBM were observed. In the subgroup analysis of high grade gliomas, RIBI that developed <6 months after radiotherapy was associated with inferior overall survival rates compared to cases of RIBI that occurred ${\geq}6$ months (p = 0.085). Conclusion: Our study demonstrated that RIBI could occur in early periods after conventional fractionated brain radiotherapy within normal tolerable dose ranges. Studies with a larger number of patients are required to identify the strong influencing factors for RIBI development.

Radiotherapy for initial clinically positive internal mammary nodes in breast cancer

  • Kim, Jina;Chang, Jee Suk;Choi, Seo Hee;Kim, Yong Bae;Keum, Ki Chang;Suh, Chang-Ok;Yang, Gowoon;Cho, Yeona;Kim, Jun Won;Lee, Ik Jae
    • Radiation Oncology Journal
    • /
    • v.37 no.2
    • /
    • pp.91-100
    • /
    • 2019
  • Purpose: Internal mammary lymph node (IMN) involvement is associated with poor prognosis in breast cancer. This study investigated the treatment outcomes of initial clinically IMN-positive breast cancer patients who received adjuvant radiotherapy (RT), including IMN irradiation, following primary breast surgery. Materials and Methods: We retrospectively reviewed data of 95 breast cancer patients with clinically detected IMNs at diagnosis treated with surgery and RT between June 2009 and December 2015. Patients received adjuvant RT to the whole breast/chest wall and regional lymph node (axillary, internal mammary, and supraclavicular) areas. Twelve patients received an additional boost to the IMN area. Results: The median follow-up was 43.2 months (range, 4.5 to 100.5 months). Among 77 patients who received neoadjuvant chemotherapy, 52 (67.5%) showed IMN normalization and 19 (24.6%) showed a partial response to IMN. There were 3 and 24 cases of IMN failure and any recurrence, respectively. The 5-year IMN failure-free survival, disease-free survival (DFS), and overall survival (OS) were 96%, 70%, and 84%, respectively. IMN failure-free survival was significantly affected by resection margin status (97.7% if negative, 87.5% for close or positive margins; p = 0.009). All three patients with IMN failure had initial IMN size ≥1 cm and did not receive IMN boost irradiation. The median age of the three patients was 31 years, and all had hormone receptor-negative tumors. Conclusion: RT provides excellent IMN control without the support of IMN surgery. Intensity-modulated radiotherapy, including IMN boost for breast cancer patients, is a safe and effective technique for regional lymph node irradiation.